Press Releases July 15, 2026 04:05 PM

PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026

PacBio schedules Q2 2026 earnings call to discuss financial results on August 5, 2026

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
PACB

Pacific Biosciences (PacBio) announced it will report its second quarter 2026 financial results on August 5, 2026, and hold a conference call to discuss these results. PacBio is a life science technology company specializing in advanced sequencing solutions for genetic research across multiple sectors.

PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026
PACB
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • PacBio will report Q2 2026 financial results on August 5, 2026.
  • The company offers advanced sequencing technologies used in various research fields including human genetics, plant and animal sciences, infectious diseases, and oncology.
  • The financial results call is accessible via webcast and phone for investors and analysts.

MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

The call will be webcast and may be accessed on PacBio’s website at https://investor.pacificbiosciences.com/.

Date: Wednesday, August 5, 2026, at 4:30 p.m. ET (1:30 p.m. PT)
Listen live via internet or replay: https://investor.pacificbiosciences.com/
Toll-free: 1-888-349-0136
International: 1-412-317-0459

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.  

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. 

Contacts

Investors:
[email protected]

Media:
[email protected]


Risks

  • Market and financial performance could be impacted if earnings do not meet expectations.
  • As products are for research use only, regulatory changes or funding shifts in life sciences research could affect demand.
  • Technological competition and development challenges in the genetic sequencing sector may affect PacBio's market position.

More from Press Releases

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 Aug 29, 2026 Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 Aug 29, 2026 20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity Aug 28, 2026 Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update Aug 28, 2026 AiRWA receives expected notification of deficiency from Nasdaq related to delayed filing of annual report on Form 10-K Aug 28, 2026